{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,11]],"date-time":"2026-10-11T12:39:45Z","timestamp":1791722385529,"version":"4.3.4"},"reference-count":24,"publisher":"American Society of Hematology","issue":"6","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,2,9]]},"abstract":"<jats:title\/>\n               <jats:p>Using 2 global postmarketing surveillance databases, Goldman and colleagues report that progressive multifocal leukoencephalopathy (PML), a viral disease associated with profound immunosuppression, occurs in approximately 0.9 cases per 1000 recipients of CD19-directed CAR T-cell therapy. The risk of PML appears higher with CAR T-cell therapy than other cancer therapies, but its precise role cannot be distinguished from antecedent therapies that these patients receive.<\/jats:p>","DOI":"10.1182\/blood.2022017386","type":"journal-article","created":{"date-parts":[[2022,11,4]],"date-time":"2022-11-04T19:58:10Z","timestamp":1667591890000},"page":"673-677","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":15,"title":["Progressive multifocal leukoencephalopathy in patients treated with chimeric antigen receptor T cells"],"prefix":"10.1182","volume":"141","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5035-100X","authenticated-orcid":false,"given":"Adam","family":"Goldman","sequence":"first","affiliation":[{"name":"1Department of Internal Medicine, The Talpiot Sheba Medical Leadership Program, Chaim Sheba Medical Center, Ramat-Gan, Israel"},{"name":"2Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0487-7996","authenticated-orcid":false,"given":"Emanuel","family":"Raschi","sequence":"additional","affiliation":[{"name":"3Pharmacology Unit, Department of Medical and Surgical Sciences, Alma Mater Studiorum - University of Bologna, Bologna, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joab","family":"Chapman","sequence":"additional","affiliation":[{"name":"4Department of Neurology, The Chaim Sheba Medical Center, Ramat-Gan, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bianca D.","family":"Santomasso","sequence":"additional","affiliation":[{"name":"5Department of Neurology, Memorial Sloan Kettering Cancer Center, New York, NY"},{"name":"6Adult Bone Marrow Transplantation Service and Cellular Therapy Service, Memorial Sloan Kettering Cancer Center, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1579-2293","authenticated-orcid":false,"given":"Marcelo C.","family":"Pasquini","sequence":"additional","affiliation":[{"name":"7Department of Medicine, Center for International Blood and Bone Marrow Transplant Research, Medical College of Wisconsin, Milwaukee, WI"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5910-4571","authenticated-orcid":false,"given":"Miguel-Angel","family":"Perales","sequence":"additional","affiliation":[{"name":"6Adult Bone Marrow Transplantation Service and Cellular Therapy Service, Memorial Sloan Kettering Cancer Center, New York, NY"},{"name":"8Department of Medicine, Weill Cornell Medical College, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9827-8032","authenticated-orcid":false,"given":"Roni","family":"Shouval","sequence":"additional","affiliation":[{"name":"6Adult Bone Marrow Transplantation Service and Cellular Therapy Service, Memorial Sloan Kettering Cancer Center, New York, NY"},{"name":"8Department of Medicine, Weill Cornell Medical College, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"1","key":"2023082817145290200_bib1","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1038\/s41582-020-00427-y","article-title":"Progressive multifocal leukoencephalopathy and the spectrum of JC virus-related disease","volume":"17","author":"Cortese","year":"2021","journal-title":"Nat Rev Neurol"},{"issue":"26","key":"2023082817145290200_bib2","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","article-title":"Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma","volume":"377","author":"Neelapu","year":"2017","journal-title":"N\u00a0Engl J Med"},{"issue":"1","key":"2023082817145290200_bib3","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1056\/NEJMoa1804980","article-title":"Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma","volume":"380","author":"Schuster","year":"2019","journal-title":"N\u00a0Engl J Med"},{"issue":"10","key":"2023082817145290200_bib4","doi-asserted-by":"crossref","first-page":"2667","DOI":"10.3324\/haematol.2020.254045","article-title":"Hematopoietic recovery and immune reconstitution after axicabtagene ciloleucel in patients with large B-cell lymphoma","volume":"106","author":"Strati","year":"2021","journal-title":"Haematologica"},{"issue":"1","key":"2023082817145290200_bib5","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1182\/bloodadvances.2020002732","article-title":"Immune reconstitution and infectious complications following axicabtagene ciloleucel therapy for large B-cell lymphoma","volume":"5","author":"Baird","year":"2021","journal-title":"Blood Adv"},{"issue":"24","key":"2023082817145290200_bib6","doi-asserted-by":"crossref","first-page":"2499","DOI":"10.1182\/blood.2020010543","article-title":"CAR-HEMATOTOX: a model for CAR T-cell-related hematologic toxicity in relapsed\/refractory large B-cell lymphoma","volume":"138","author":"Rejeski","year":"2021","journal-title":"Blood"},{"issue":"1","key":"2023082817145290200_bib7","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1007\/s12185-020-02840-x","article-title":"Progressive multifocal leukoencephalopathy after CAR T therapy","volume":"112","author":"Sdrimas","year":"2020","journal-title":"Int J Hematol"},{"issue":"4","key":"2023082817145290200_bib8","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1002\/jha2.274","article-title":"Pembrolizumab for the treatment of progressive multifocal leukoencephalopathy following anti-CD19 CAR-T therapy: a case report","volume":"2","author":"Mackenzie","year":"2021","journal-title":"eJHaem"},{"issue":"4","key":"2023082817145290200_bib9","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1111\/ejh.13583","article-title":"Late occurrence of progressive multifocal leukoencephalopathy after anti-CD19 chimeric antigen receptor T-cell therapy","volume":"106","author":"Mian","year":"2021","journal-title":"Eur J Haematol"},{"issue":"12","key":"2023082817145290200_bib10","doi-asserted-by":"crossref","first-page":"e870","DOI":"10.1016\/S2352-3026(21)00316-1","article-title":"Progressive multifocal leukoencephalopathy in the era of chimeric antigen receptor T-cell therapy","volume":"8","author":"Mackenzie","year":"2021","journal-title":"Lancet Haematol"},{"issue":"6","key":"2023082817145290200_bib11","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1002\/pds.1742","article-title":"Quantitative signal detection using spontaneous ADR reporting","volume":"18","author":"Bate","year":"2009","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"6","key":"2023082817145290200_bib12","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1038\/clpt.2013.24","article-title":"Performance of pharmacovigilance signal-detection algorithms for the FDA Adverse Event Reporting System","volume":"93","author":"Harpaz","year":"2013","journal-title":"Clin Pharmacol Ther"},{"key":"2023082817145290200_bib13","author":"Moskop","year":"2020"},{"issue":"4","key":"2023082817145290200_bib14","doi-asserted-by":"crossref","DOI":"10.1111\/ene.13906","article-title":"The spectrum of progressive multifocal leukoencephalopathy: a practical approach","volume":"26","author":"Bartsch","year":"2019","journal-title":"Eur J Neurol"},{"issue":"20","key":"2023082817145290200_bib15","doi-asserted-by":"crossref","first-page":"4834","DOI":"10.1182\/blood-2008-10-186999","article-title":"Progressive multifocal leukoencephalopathy after rituximab therapy in HIV-negative patients: a report of 57 cases from the Research on Adverse Drug Events and Reports project","volume":"113","author":"Carson","year":"2009","journal-title":"Blood"},{"issue":"5","key":"2023082817145290200_bib16","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1016\/S1474-4422(18)30040-1","article-title":"Pathogenesis of progressive multifocal leukoencephalopathy and risks associated with treatments for multiple sclerosis: a decade of lessons learned","volume":"17","author":"Major","year":"2018","journal-title":"Lancet Neurol"},{"issue":"20","key":"2023082817145290200_bib17","doi-asserted-by":"crossref","first-page":"1870","DOI":"10.1056\/NEJMoa1107829","article-title":"Risk of natalizumab-associated progressive multifocal leukoencephalopathy","volume":"366","author":"Bloomgren","year":"2012","journal-title":"N\u00a0Engl J Med"},{"issue":"20","key":"2023082817145290200_bib18","doi-asserted-by":"crossref","first-page":"1697","DOI":"10.1212\/WNL.0b013e31821a446b","article-title":"Clinical outcomes of natalizumab-associated progressive multifocal leukoencephalopathy","volume":"76","author":"Vermersch","year":"2011","journal-title":"Neurology"},{"issue":"8","key":"2023082817145290200_bib19","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1016\/S1474-4422(21)00174-5","article-title":"BK virus-specific T cells for immunotherapy of progressive multifocal leukoencephalopathy: an open-label, single-cohort pilot study","volume":"20","author":"Cortese","year":"2021","journal-title":"Lancet Neurol"},{"issue":"17","key":"2023082817145290200_bib20","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1056\/NEJMoa1815039","article-title":"Pembrolizumab treatment for progressive multifocal leukoencephalopathy","volume":"380","author":"Cortese","year":"2019","journal-title":"N\u00a0Engl J Med"},{"issue":"8","key":"2023082817145290200_bib21","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1001\/jamaneurol.2014.825","article-title":"Treatment of progressive multifocal leukoencephalopathy with interleukin 7","volume":"71","author":"Alstadhaug","year":"2014","journal-title":"JAMA Neurol"},{"key":"2023082817145290200_bib22","doi-asserted-by":"crossref","first-page":"241","DOI":"10.3389\/fimmu.2015.00241","article-title":"B cells and progressive multifocal leukoencephalopathy: search for the missing link","volume":"6","author":"Durali","year":"2015","journal-title":"Front Immunol"},{"issue":"8","key":"2023082817145290200_bib23","doi-asserted-by":"crossref","first-page":"e593","DOI":"10.1016\/S2352-3026(21)00167-8","article-title":"Progressive multifocal leukoencephalopathy in patients treated with rituximab: a 20-year review from the Southern Network on Adverse Reactions","volume":"8","author":"Bennett","year":"2021","journal-title":"Lancet Haematol"},{"issue":"10","key":"2023082817145290200_bib24","doi-asserted-by":"crossref","first-page":"1643","DOI":"10.1038\/s41409-019-0487-3","article-title":"Early and late hematologic toxicity following CD19 CAR-T cells","volume":"54","author":"Fried","year":"2019","journal-title":"Bone Marrow Transplant"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/141\/6\/673\/2075071\/blood_bld-2022-017386-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/141\/6\/673\/2075071\/blood_bld-2022-017386-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,28]],"date-time":"2023-08-28T17:15:23Z","timestamp":1693242923000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/141\/6\/673\/487023\/Progressive-multifocal-leukoencephalopathy-in"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2,9]]},"references-count":24,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2023,2,9]]}},"URL":"https:\/\/doi.org\/10.1182\/blood.2022017386","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,2,9]]}}}